VIGL: Rega marang dodolan Vigil Neuroscience
Adherence to ESG standards obligates Vigil Neuroscience (VIGL) to minimize environmental impact through energy-saving measures in its laboratories. The current P/S ratio visualizes the market valuation of these expenditures, where reflects the latest value of the metric. Asset value here is driven by science rather than GDP, which guarantees macro-stability. This stability is further supported by a strong staff of neuroimmunologists and the targeted hiring of clinical research experts.
Rincian metrik lan analitis perusahaan Vigil Neuroscience (VIGL)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Modal Vigil Neuroscience|VIGL - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal vigilneuro.com|VIGL - Gunggung utang perusahaan|Utang marang nilai buku Vigil Neuro|VIGL - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Vigil Neuroscience|Likuiditas darurat vigilneuro.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
VIGL - Bathi resik perusahaan|Prakiraan bathi resik Vigil Neuroscience|VIGL - Pangali P/E|Prakiraan rega marang bathi vigilneuro.com|VIGL - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Vigil Neuro|VIGL - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Vigil Neuroscience|VIGL - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan vigilneuro.com|VIGL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Vigil Neuroscience
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:VIGL (Vigil Neuroscience Inc.)
The market capitalization-to-revenue dynamics of Vigil Neuroscience (VIGL) reflect market expectations regarding the company's expansion into the immunological therapy segment for dementia and rare brain pathologies. This multiple is calculated by dividing the total business value by its annual turnover, allowing investors to assess the asset's degree of overvaluation and determine optimal entry points while accounting for capital stagnation risks.
Perusahaan pesaing
biogen.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Rega marang dodolan|AXSM: Kapitalisasi marang pendapatan|ACAD - Multiplikator P/S|Xenon Pharmaceuticals (XENE) - Rasio rega marang pendapatan|vikingtherapeutics.com - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Supernus|Rega marang dodolan Catalyst Pharma CPRX|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|Koefisien rega marang pendapatan Harmony Corp|Multiplikator P/S BHVN (Biohaven Ltd.)|AMLX - Kapitalisasi marang pendapatan|Trevi Therapeutics, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Praxis Precision Medicines Inc PRAX|AVXL: Multiplikator P/S|Rega marang dodolan CeriBell EEG (CBLL)|Rasio rega marang pendapatan Prothena Biosciences|Rasio kapitalisasi marang pendapatan ALEC (Alector Therapeutics)|Multiplikator P/S ANNX|Kapitalisasi marang pendapatan omeros.com OMER|Multiplikator P/S NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Rega marang dodolan|VYGR: Kapitalisasi marang pendapatan|NMRA: Rasio rega marang pendapatan|SCLX: Multiplikator P/S|TVGN - Koefisien rega marang pendapatan|ACOG (Alpha Cognition Inc) - Multiplikator P/S|CGTX - Multiplikator rega marang pendapatan|Rasio rega marang pendapatan Inhibikase Therapeutics (IKT)|Rasio rega marang pendapatan SAVA (cassavasciences.com)|Rasio rega marang pendapatan Assertio ASRT|COYA: Rasio kapitalisasi marang pendapatan|VistaGen Therapeutics Inc - Multiplikator P/S|Rega marang dodolan Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Kapitalisasi marang pendapatan|cervomed.com (CRVO) - Multiplikator P/S|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|CLNN: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan PepGen Inc. (PEPG)|JUNS - Rega marang dodolan|Relmada Therapeutics - Kapitalisasi marang pendapatan|annovisbio.com - Rasio rega marang pendapatan|Grace Tx - Multiplikator P/S|Koefisien rega marang pendapatan Firefly Neuroscience, Inc. AIFF|KLTO: Multiplikator P/S|Multiplikator rega marang pendapatan NeuroSense Therapeutics Ltd. NRSN|RVPH (Reviva Pharmaceuticals) - Multiplikator P/S|MetaVia, Inc. (MTVA) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan NeurAxis (NRXS)|Rasio rega marang pendapatan HSDT (heliusmedical.com)|Passage Bio - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan NEUP|NERV - Rasio rega marang pendapatan|ATHA (athira.com) - Rasio kapitalisasi marang pendapatan|ADXN: Multiplikator P/S|Rega marang dodolan Alzamend Neuro (ALZN)|Kapitalisasi marang pendapatan CYCN|Multiplikator P/S Protagenic|Rasio rega marang pendapatan Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. (BCLI) - Rega marang dodolan|CARA - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Chromocell CHRO|ELYM: Multiplikator P/S|Kapitalisasi marang pendapatan Intra-Cellular Therapies, Inc.|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator P/S|Marinus Pharmaceuticals Inc (MRNS) - Koefisien rega marang pendapatan|Multiplikator P/S NKGN|NRBO - Rega marang dodolan|Rasio rega marang pendapatan Sage Therapeutics, Inc. SAGE|SNPX: Rasio kapitalisasi marang pendapatan|Trevena - Multiplikator P/S|anewmeds.com (WENA) - Kapitalisasi marang pendapatan|CERE: Multiplikator P/S
